Notice of Intent: Analytics Drug Research Advisor, OFF-X (Translational Safety/Toxicology), and Cortellis Drug Discovery Intelligence Software
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a separate written solicitation will not be issued. The solicitation number is 75N95021Q00113 and the solicitation is issued as a Request for Quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; and FAR Part 12—Acquisition of Commercial Items and is not expected to exceed the simplified acquisition teshold. A fixed-price type of purchase order is contemplated for this requirement. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The Office of Translational Initiatives and Program Innovations (OTIPI) requires the renewal of its user license and subscription to the Clarivate Analytics Drug Research Advisor, OFF-X (Translational Safety/Toxicology), and Cortellis Drug Discovery Intelligence software application with BioMarkers Module from Clarivate Analytics LLC. These applications support OTIPI’s SBIR/STTR Business Program, Ladder U18 program (Value Ladder: climbing out of valley of death), and various Translational Initiatives. The SBIR/STTR Business Program utilizes the database to identify Pharmaceutical companies interested in investing in NIDA funded SBIR/STTR companies. The Translational and U18 Initiatives uses this software to identify promising drugs, formulations, and models in the development phase that are not currently used in the substance abuse ecosystem. See Attachment 1 – Purchase Description, for additional details. The solicitation document and incorporated provisions and clauses are those in effect tough Federal Acquisition Circular 2021-05, dated 03/10/2021. The North American Industry Classification System (NAICS) code for this procurement is 519130 - Internet Publishing and Broadcasting and Web Search Portals. This requirement is not a small business set aside. This acquisition shall consist of: Line 1 – One-year access to Drug Research Advisor - Target Druggability Line 2 – One-year access to Cortellis Drug Discovery Intelligence Line 3 – One-year access to Cortellis Drug Discovery Intelligence – Biomarkers Module Line 4 – One-year access to OFF-X (Translational Safety/Toxicology) NIDA anticipates the use of Options in accordance with FAR 52.217-9, Option to Extend the Term of the Contract. The estimated period of performance shall be as follows: Base Period – April 1, 2021 tough March 31, 2022; Option Period 1 – April 1, 2022 tough March 31, 2023; Option Period 2 – April 1, 2023 tough March 31, 2024; The ultimate period of performance if all options are exercised shall be April 1, 2021 tough March 31, 2024. Delivery shall be to: Ram Arudchandran, PhD, Program Officer, Health Scientist Administrator Office of Translational Initiatives and Program Innovations (OTIPI) National Institute on Drug Abuse Delivery shall be completed by the effective date of order. The provision at FAR Clause 52.212-1 Instructions to Offerors—Commercial Items is applicable to this solicitation. An award will be made to the offer that is the lowest evaluated price and meets or exceeds the acceptability standards for non-price factors. The non-price factors include the demonstrated technical capability to comply with the salient characteristics, the inclusion of Options as stated in the Purchase Description, as well as past performance. The provision at FAR clause 52.212-2, Evaluation – Commercial Items, applies to this acquisition. All offerors evaluated based on technical acceptability described in Attachment 1 - Purchase Description and proposed prices and Options will be evaluated on price reasonableness. Offerors price quote will be evaluated for reasonableness. For a price to be reasonable, it must represent a price to the government that a prudent person would pay when consideration is given to prices in the market. Normally, price reasonableness is established tough adequate price competition, but may also be determined tough cost and price analysis techniques. Price evaluation will not be conducted on any Offeror determined to be technically unacceptable. The Offeror is to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications—Commercial Items, with its offer. The Offeror is to include a completed and signed copy of FAR 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment. (Aug 2020), with its offer. The provision at FAR Clause 52.212-4, Contract Terms and Conditions—Commercial Items, applies to this acquisition. See Attachment 2 – Commercial Contract Terms and Conditions. The provision of FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items, applies to this acquisition. See Attachment 2 – Commercial Contract Terms and Conditions. The Contractor shall comply with the following Federal Acquisition Regulation (FAR) clauses, which are incorporated in this contract by reference, to implement provisions of law or Executive orders applicable to acquisitions of commercial items: FAR 52.203-19, Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements (Jan 2017) (section 743 of Division E, Title VII, of the Consolidated and Further Continuing Appropriations Act, 2015 (Pub. L. 113-235) and its successor provisions in subsequent appropriations acts (and as extended in continuing resolutions)). FAR 52.204-23, Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities (Jul 2018) (Section 1634 of Pub. L. 115-91). FAR 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment. (Aug 2020). FAR 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment. (Aug 2020). FAR 52.209-10, Prohibition on Contracting with Inverted Domestic Corporations (Nov 2015). FAR 52.233-3, Protest After Award (Aug 1996) (31 U.S.C. 3553). FAR 52.233-4, Applicable Law for Breach of Contract Claim (Oct 2004) (Public Laws 108-77 and 108-78 (19 U.S.C. 3805 note)). FAR Subpart 17.2 Option Provisions. Specifically, FAR 52.217-5, Evaluation of Options FAR 52.217-8, Option to Extend Services and FAR 52.217-9, Option to Extend the Term of the Contract shall be incorporated in the contract. FAR 52.232-39 Unenforceability of Unauthorized Obligations (JUN 2013) The Contractor shall comply with the following FAR clauses: 52.204-10 Reporting Executive Compensation and First-Tier Subcontract Awards (Oct 2016) 52.219-28 Post Award Small Business Program Representation (JUL 3013) 52.222-3 Convict Labor (June 2003). 52.222-19 Child Labor—Cooperation with Authorities and Remedies (Oct 2016) 52.222-21 Prohibition of Segregated Facilities (Apr 2015). 52.222-26 Equal Opportunity (Sept 2016). 52.222-36 Equal Opportunity for Workers with Disabilities (JUL 2014) 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (DEC 2010) 52.222-50 Combating Trafficking in Persons (March 2015) 52.223-18 Encouraging Contractor Policies to Ban Text Messaging While Driving (Aug 2011) 52.225-13 Restrictions on Certain Foreign Purchases (June 2008) 52.232-33 Payment by Electronic Funds Transfer— System for Award Management (JUL 2013). The following additional contract requirement(s) or terms and conditions as determined by the contracting officer are necessary for this acquisition and consistent with customary commercial practices. Attachment 1 – Purchase Description Attachment 2 – Commercial Contract Terms and Conditions Attachment 3 – Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment Attachment 4 – Invoice Instructions The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this solicitation must include enough information to establish the interested parties’ bona-fide capabilities of providing the product or service. A determination by the Government whether to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered to determine whether to proceed on a non-competitive basis as indicated above, or to conduct a competitive procurement. The response to the combined synopsis/solicitation is due no later than March 26, 2021 at 1:00 P.M. Eastern Standard Time (EST). Quotes submitted after the deadline may not be considered. The response must be submitted in a “read-only” electronic format to the Contracting Officer, Josh Lazarus at josh.lazarus@nih.gov. In the response, Offerors shall cite the RFQ number 75N95021Q00113 and the name of firm in the subject line of email submittal. Fax responses will not be accepted. In addition, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All Offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
75N95021Q00113 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
3/24/21, 4:45 PM Notice of Intent: Analytics Drug Research Advisor, OFF-X (Translational Safety/Toxicology), and Cortellis Drug Discovery Intelligence Software
INTRODUCTION PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION. THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Contracts Management Branch – Red (CMB) on behalf of the NIDA, Intramural Research Program (NIDA-IRP) intends to award a sole source contract to Clarivate Analytics for a software subscription and user license to the Drug Research Advisor and Cortellis Drug Discovery Intelligence software application with BioMarkers Module from Clarivate Analytics LLC without providing for full or open competition. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses of the Federal Acquisition Regulation (FAR) in effect tough the Federal Acquisition Circular (FAC) 2021-04. STATUTORY AUTHORITY This acquisition is conducted as non-competitive under the authority of 41 U.S.C. 253(c) under provisions of the statutory authority of FAR Subpart 6.302-1 – Only one responsible source and no other supplies or services will satisfy agency requirements. DESCRIPTION OF REQUIREMENT The Office of Translational Initiatives and Program Innovations (OTIPI) is seeking to renew its user license and subscription to the Clarivate Analytics Drug Research Advisor and Cortellis Drug Discovery Intelligence software application. OTIPI has used the Drug Research Advisor and Cortellis Drug Discovery Intelligence software application software since 2014 and completed various projects related to the SBIR/STTR Business Program and Translational Initiatives. The database is used a) to identify Pharmaceutical companies interested in investing in NIDA funded SBIR/STTR companies; b) to identify promising drugs, formulations, and models which are not currently used in the substance abuse ecosystem, and c) to identify the history of the research and development related to the specific biological target. Purpose and Objectives The Integrity Internet Access subscription from Clarivate Analytics supported OTIPI’s SBIR/STTR Business Program, Ladder U18 program (Value Ladder: climbing out of valley of death), and various Translational Initiatives. The SBIR/STTR Business Program utilizes the database to identify Pharmaceutical companies interested in investing in NIDA funded SBIR/STTR companies. The Translational and U18 Initiatives uses this software to identify promising drugs, formulations, and models in the development phase that are not currently used in the substance abuse ecosystem. Period of Performance: The estimated period of performance shall be 04/1/2021 tough 03/31/2022. Additionally, two option periods shall also be quoted by the contractor. Option Year One’s period shall be 04/1/2022 tough 03/31/2023. Option Year Two’s period shall be 04/1/2023 tough 03/31/2024. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. An interested Offeror must be able to demonstrate its capabability to independently, and not as an agent of the Government, software that provides a comprehensive database of refined drug development information and serves as an efficient system to identify promising drugs, formulations, and models in the development phase. Drug information must be integrated in a single, flexible resource, and updated daily. The software must also include information about similar chemical structures of alternative compounds, the most relevant animal models used within the scientific industry for a specific target, and identify Pharmaceutical companies interested in investing in NIDA funded SBIR/STTR companies. Responses to this notice must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by March 19, 2021, 12:00 p.m. Eastern Time and must reference number 75N95021Q00113. Responses must be submitted electronically to Josh Lazarus, Contracting Officer at josh.lazarus@nih.gov and must reference the solicitation number 75N95021Q00113 on your electronic request. FAX requests are not accepted. “All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.”
75N95021Q00113 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
3/17/21, 4:12 PM